<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04060342</url>
  </required_header>
  <id_info>
    <org_study_id>GB1275-1101 (KEYNOTE-A36)</org_study_id>
    <nct_id>NCT04060342</nct_id>
  </id_info>
  <brief_title>GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma</brief_title>
  <official_title>A Phase 1/2, First-in-Human, Open-label, Dose Escalation Study of GB1275 Monotherapy and in Combination With an Anti-PD-1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma, Followed by Basket Expansion of GB1275 With Standard of Care or in Combination With an Anti-PD-1 Antibody in Patients With Specified Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gossamer Bio Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase&#xD;
      1 Dose Escalation phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in&#xD;
      combination with Standard of Care in Patients with Metastatic Pancreatic Adenocarcinoma&#xD;
      followed by a Phase 2 Basket Expansion phase in Patients with Specified Metastatic Solid&#xD;
      Tumors&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2019</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Phase 1 - Dose Escalation of 3 different Regimen and Expansion Phase 2 - Basket of 3 Cohorts</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 - Regimens A, B,and C: Incidence of dose limiting toxicities (DLTs)</measure>
    <time_frame>Regimen A and B dose escalation Days 1-21, Regimen C dose escalations Days 1-36 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 - Regimens A, B,and C: Incidence of adverse events (AEs)</measure>
    <time_frame>Regimen A, B, and C dose escalation from baseline through 30 days last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 - Regimens A and B: Cmax of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 - Regimens A and B: Ctrough of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Trough observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 - Regimens A and B: Tmax of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Time of maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 - Regimens A and B: t1/2 of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Terminal phase elimination half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 - Regimens A and B: AUC of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Area under the plasma concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 - Regimens A and B: CL/F of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Oral clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 - Basket Cohorts 1, 2 and 3: Objective Response Rate (ORR)</measure>
    <time_frame>24 months</time_frame>
    <description>ORR defined as the proportion of subjects with best overall confirmed response (BOCR) of either a complete response (CR) or partial response (PR) as assessed by the Investigator based on RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - Regimen C: Cmax of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - Regimen C: Ctrough of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Trough observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - Regimen C: Tmax of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Time of maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - Regimen C: t1/2 of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Terminal phase elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - Regimen C: AUC of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Area under the plasma concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - Regimen C: CL/F of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Oral clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - Regimen C: Cmax of nab-paclitaxel and gemcitabine</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - Regimen C: Tmax of nab-paclitaxel and gemcitabine)</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Time of maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - Regimen C: AUC of nab-paclitaxel and gemcitabine</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Area under the plasma concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Basket Cohorts 1, 2, and 3: Duration of Response (DOR)</measure>
    <time_frame>24 months</time_frame>
    <description>DOR defined as time from date of objective response to first documented date of disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Basket Cohorts 1, 2, and 3: Time to Response (TTR)</measure>
    <time_frame>24 months</time_frame>
    <description>TTR defined as time from first dose to first date of objective response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Basket Cohorts 1, 2, and 3: Clinical Benefit Rate (CBR)</measure>
    <time_frame>6 months</time_frame>
    <description>CBR defined as proportion of subjects with confirmed CR, PR, or stable disease (SD) at six months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Basket Cohorts 1, 2, and 3: Progression Free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>PFS defined as time from first dose to first documented date of disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Basket Cohorts 1, 2, and 3: Time to Progression (TTP)</measure>
    <time_frame>24 months</time_frame>
    <description>TTP defined as time from first dose to first documented date of disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Basket Cohorts 1, 2, and 3: Overall Survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>OS defined as time from first dose to date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Basket Cohorts 1, 2, and 3: Incidence of AEs</measure>
    <time_frame>Basket Cohorts 1, 2 and 3 from baseline through 30 days last dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Basket Cohort 1, 2 and 3: PK profile of GB1275</measure>
    <time_frame>Basket Cohorts 1, 2, and 3 from baseline through 30 days last dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">242</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <condition>Esophageal Adenocarcinoma</condition>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <condition>Gastric Adenocarcinoma</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Castration-resistant Prostate Cancer</condition>
  <condition>Microsatellite Stable Colorectal Cancer</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Small-cell Lung Cancer</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Urothelial Carcinoma</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Phase 1: Regimen A - GB1275 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GB1275 Monotherapy dose escalation: Oral administration. Twice per day (BID).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Regimen B - GB1275 with an Anti-PD-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GB1275 with pembrolizumab dose escalation and expansion:&#xD;
GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Regimen C - GB1275 with Standard of Care (SOC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GB1275 with SOC dose escalation:&#xD;
GB1275 oral administration; twice per day (BID), and nab-paclitaxel and gemcitabine per United States Prescribing Information (USPI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Cohort 1 - GB1275 with SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GB1275 with SOC Basket Cohort in patients with newly diagnosed metastatic pancreatic cancer:&#xD;
GB1275 oral administration; twice per day (BID) and nab-paclitaxel and gemcitabine per USPI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Cohort 2 - GB1275 with an Anti-PD-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GB1275 with pembrolizumab Basket Cohort in patients with MSS colorectal cancer:&#xD;
GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Cohort 3 - GB1275 with an Anti-PD-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GB1275 with pembrolizumab Basket Cohort in patients with gastric/GEJ cancer, PD-L1 positive:&#xD;
GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GB1275</intervention_name>
    <description>Oral</description>
    <arm_group_label>Phase 1: Regimen A - GB1275 monotherapy</arm_group_label>
    <arm_group_label>Phase 1: Regimen B - GB1275 with an Anti-PD-1</arm_group_label>
    <arm_group_label>Phase 1: Regimen C - GB1275 with Standard of Care (SOC)</arm_group_label>
    <arm_group_label>Phase 2: Cohort 1 - GB1275 with SOC</arm_group_label>
    <arm_group_label>Phase 2: Cohort 2 - GB1275 with an Anti-PD-1</arm_group_label>
    <arm_group_label>Phase 2: Cohort 3 - GB1275 with an Anti-PD-1</arm_group_label>
    <other_name>Investigational</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel and gemcitabine</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Phase 1: Regimen C - GB1275 with Standard of Care (SOC)</arm_group_label>
    <arm_group_label>Phase 2: Cohort 1 - GB1275 with SOC</arm_group_label>
    <other_name>Abraxane and Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Phase 1: Regimen B - GB1275 with an Anti-PD-1</arm_group_label>
    <arm_group_label>Phase 2: Cohort 2 - GB1275 with an Anti-PD-1</arm_group_label>
    <arm_group_label>Phase 2: Cohort 3 - GB1275 with an Anti-PD-1</arm_group_label>
    <other_name>Anti-PD-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group&#xD;
             (ECOG) Performance Scale.&#xD;
&#xD;
          -  Women of childbearing potential must use an acceptable method of contraception&#xD;
&#xD;
        Phase 1&#xD;
&#xD;
        Subjects with the the following:&#xD;
&#xD;
          -  Regimen A and B:&#xD;
&#xD;
               -  pancreatic adenocarcinoma,&#xD;
&#xD;
               -  esophageal adenocarcinoma, or esophageal squamous cell carcinoma, or&#xD;
&#xD;
               -  gastric/gastroesophageal junction adenocarcinoma, or&#xD;
&#xD;
               -  TNBC, or&#xD;
&#xD;
               -  prostate cancer, or&#xD;
&#xD;
               -  colorectal adenocarcinoma, or subjects with tumor types that have progressed&#xD;
                  after receiving initial treatment benefit rom the last single agent checkpoint&#xD;
                  inhibitor that is approved for the indication or in combination with standard of&#xD;
                  care therapy, for example, non-small cell lung cancer, small cell lung cancer,&#xD;
                  head and neck squamous cell carcinoma, urothelial carcinoma, renal cell&#xD;
                  carcinoma, and hepatocellular carcinoma, etc.&#xD;
&#xD;
          -  Regimen C: newly diagnosed stage IV pancreatic cancer&#xD;
&#xD;
        Phase 2&#xD;
&#xD;
          -  Cohort 1: pancreatic cancer.&#xD;
&#xD;
          -  Cohort 2: colorectal cancer&#xD;
&#xD;
          -  Cohort 3: gastric/GEJ adenocarcinoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of another malignancy within 2 years prior to first study drug(s)&#xD;
             administration, unless the malignancy was treated with curative intent and the&#xD;
             likelihood of relapse is &lt;5% in 2 years&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Known history of testing positive for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Gastrointestinal (GI) tract disease causing the inability to take oral medication.&#xD;
&#xD;
          -  Positive test for Hepatitis B virus surface antigen (HBsAg) or a and/or positive Hep C&#xD;
             antibody result with detectable hepatitis C virus (HCV) ribonucleic acid (RNA)&#xD;
             indicating acute or chronic infection.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria will apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.</last_name>
    <phone>1-866-668-4083</phone>
    <email>ClinicalTrials@gossamerbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Hospital, Anschutz Cancer Pavilion (ACP)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine - Siteman Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Sarah Cannon Research Institute/Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royals Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2019</study_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GEJ adenocarcinoma</keyword>
  <keyword>TNBC</keyword>
  <keyword>MSS mCRC</keyword>
  <keyword>PD-L1 + gastric cancer</keyword>
  <keyword>PD-L1 positive gastric cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>SCLC</keyword>
  <keyword>newly diagnosed stage IV pancreatic adenocarcinoma</keyword>
  <keyword>HCC</keyword>
  <keyword>RCC</keyword>
  <keyword>HNSCC</keyword>
  <keyword>Transitional Cell Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

